80 related articles for article (PubMed ID: 14532845)
1. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
2. Expression in Escherichia Coli, Purification, and Functional Reconstitution of Human Steroid 5α-Reductases.
Peng HM; Valentín-Goyco J; Im SC; Han B; Liu J; Qiao J; Auchus RJ
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32716491
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment.
Mandour AA; Elkaeed EB; Hagras M; Refaat HM; Ismail NS
Future Med Chem; 2023 Dec; 15(23):2149-2163. PubMed ID: 37955117
[No Abstract] [Full Text] [Related]
4. Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system.
Pais P; Villar A; Rull S
Res Rep Urol; 2016; 8():41-9. PubMed ID: 27186566
[TBL] [Abstract][Full Text] [Related]
5. Possible clinical implications of prostate capsule thickness and glandular epithelial cell density in benign prostate hyperplasia.
Holder KG; Galvan B; Knight AS; Ha F; Collins R; Weaver PE; Brandi L; de Riese WT
Investig Clin Urol; 2021 Jul; 62(4):423-429. PubMed ID: 34085792
[TBL] [Abstract][Full Text] [Related]
6. Spatial architectures of somatic mutations in normal prostate, benign prostatic hyperplasia and coexisting prostate cancer.
Chae J; Jung SH; Choi EJ; Kim JW; Kim NY; Moon SW; Lee JY; Chung YJ; Lee SH
Exp Mol Med; 2024 Feb; 56(1):168-176. PubMed ID: 38172600
[TBL] [Abstract][Full Text] [Related]
7. Protective Role of 4-(4-Hydroxy-3-methoxyphenyl)-2-Butanone on Prostatic Cells Hyperplasia of Rats and Human, 5α-reductase Inhibition Pathway.
Ahmed AS; Soliman MG
J Microsc Ultrastruct; 2021; 9(4):164-169. PubMed ID: 35070691
[TBL] [Abstract][Full Text] [Related]
8. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Buhigas C; Warren AY; Leung WK; Whitaker HC; Luxton HJ; Hawkins S; Kay J; Butler A; Xu Y; Woodcock DJ; Merson S; Frame FM; Sahli A; Abascal F; ; Martincorena I; Bova GS; Foster CS; Campbell P; Maitland NJ; Neal DE; Massie CE; Lynch AG; Eeles RA; Cooper CS; Wedge DC; Brewer DS
Mol Cancer; 2022 Sep; 21(1):183. PubMed ID: 36131292
[TBL] [Abstract][Full Text] [Related]
9. The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy.
Lemos G; Fernandes CMAS; Silva FH; Calmasini FB
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):230-238. PubMed ID: 38297152
[TBL] [Abstract][Full Text] [Related]
10. Benign and malignant prostate neoplasms show different spatial organization of collagen.
Zadvornyi T; Lukianova N; Mushii O; Pavlova A; Voronina O; Chekhun V
Croat Med J; 2023 Dec; 64(6):413-420. PubMed ID: 38168522
[TBL] [Abstract][Full Text] [Related]
11. Fabrication of Antibody Conjugated Super Magnetic Oxide Nanoparticles for Early Detection of Prostate Cancer.
Nayerpour Dizaj T; Jafari-Gharabaghlou D; Farhoudi Sefidan Jadid M; Jahanban R; Rahimi M; Farajollahi MM; Mohsenzadegan M; Zarghami N
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2089-2097. PubMed ID: 37378940
[TBL] [Abstract][Full Text] [Related]
12. Virtual Insights into Natural Compounds as Potential 5α-Reductase Type II Inhibitors: A Structure-Based Screening and Molecular Dynamics Simulation Study.
Shaikh S; Ali S; Lim JH; Ahmad K; Han KS; Lee EJ; Choi I
Life (Basel); 2023 Nov; 13(11):. PubMed ID: 38004292
[TBL] [Abstract][Full Text] [Related]
13. Chickpea Sprouts as a Potential Dietary Support in Different Prostate Disorders-A Preliminary In Vitro Study.
Galanty A; Prochownik E; Grudzińska M; Paśko P
Molecules; 2024 Feb; 29(5):. PubMed ID: 38474555
[TBL] [Abstract][Full Text] [Related]
14. Two New Components from an Association of Marine Sponges
Hwang BS; Lee S; Jeong EJ; Rho JR
Mar Drugs; 2023 Sep; 21(9):. PubMed ID: 37755104
[TBL] [Abstract][Full Text] [Related]
15.
Shareef ZA; Hachim MY; Talaat IM; Bhamidimarri PM; Ershaid MNA; Ilce BY; Venkatachalam T; Eltayeb A; Hamoudi R; Hachim IY
Front Immunol; 2023; 14():978236. PubMed ID: 36845147
[TBL] [Abstract][Full Text] [Related]
16. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.
Olesovsky C; Kapoor A
Ther Adv Urol; 2016 Aug; 8(4):257-271. PubMed ID: 27928428
[TBL] [Abstract][Full Text] [Related]
18. SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.
Aggarwal S; Singh M; Kumar A; Mukhopadhyay T
Mol Cell Biochem; 2015 Oct; 408(1-2):15-23. PubMed ID: 26092425
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.
Wang K; Fan DD; Jin S; Xing NZ; Niu YN
Asian J Androl; 2014; 16(2):274-9. PubMed ID: 24457841
[TBL] [Abstract][Full Text] [Related]
20. Androgen action in prostate cancer.
Basu S; Tindall DJ
Horm Cancer; 2010 Oct; 1(5):223-8. PubMed ID: 21761368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
